老虎证券

BUZZ-Mersana rises on FDA's 'fast track' tag for cancer drug, early-stage trial data

Reuters
01/10
BUZZ-Mersana rises on FDA's 'fast track' tag for cancer drug, early-stage trial data

** Shares of drug developer Mersana Therapeutics MRSN.O rise 5.38% to $1.38 premarket

** Co says U.S. FDA has granted additional fast track tag to its experimental drug XMT-1660

** The new tag is for the treatment of some patients with a type of breast cancer

** The FDA's Fast Track program is designed to facilitate the development and expedite the review of drug candidates to treat serious conditions and fill an unmet medical need

** Separately, co announced data from an early-stage trial of the drug in patients with a type of breast cancer

** Stock fell 38.36% last year

(Reporting by Sriparna Roy in Bengaluru)

((Sriparna.Roy@thomsonreuters.com;))

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10